Elizabeth is a strategic global business partner and advisor with 17+ years of experience bridging intellectual property with business strategy across pharma, biotech, and life sciences (Novo Nordisk, Ferring and Coloplast). Purpose-driven mindset with full-spectrum cradle to grave IP global support for multiple pipeline assets at all stages of research, development and commercialisation.

Combining scientific depth (PhD in Health Sciences), legal expertise (European and Danish Patent Attorney), and business acumen (Executive MBA), she partners with biotech and life science founders, investors, and executive teams to translate science into investable, scalable assets.

Elizabeth has a thorough understanding of patent law in major jurisdictions and a strong grasp of regulatory pathways, enabling her to deliver holistic, globally aligned IP strategies. Known for analytical clarity and strong communication, she provides pragmatic, tailored advice that supports decision‑making and accelerates innovation.

Experience in varied industries, therapy areas and modalities. Thorough experience in licensing, acquisitions and collaborations, including IP and licensing strategies, and major regulatory pathways for innovators as well as evaluating risks of generics and biosimilars. Excels at balancing practical legal advice and analysis to the C-suite and executive board with a strong commercial orientation.